CHECK THE STUDIES
Semaglutide references let you check each study result.
You can open every study and review. Take a paper to your doctor if you wish.
These papers back the weight, heart, kidney, and liver findings
Want to check a claim? Here’s what the papers cover: safety, weight, liver, heart, and kidney results.
Several papers report weight changes. SUSTAIN-6 covers the heart, while other studies cover the kidneys and liver.
SURMOUNT-5 compares two weight medicines. Safety reviews tell you which risks look clear and which still have doubt.
Each link opens the full paper in a medical library or journal. You may take that paper to your doctor.
The papers won’t all be easy reading. Still, you can check whether a result says what the page claims.
- Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. ↗
- Marso SP, et al. (SUSTAIN-6 Investigators). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. ↗
- Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. ↗
- Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020. ↗
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. ↗
- Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. ↗
- Aronne LJ, et al. (SURMOUNT-5 Investigators). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. ↗
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022. ↗
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021. ↗
- Davies M, et al. (STEP 2 Study Group). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021. ↗
- Mahapatra MK, et al. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases. Pharm Res. 2022. ↗
- Sanyal AJ, et al. (ESSENCE Study Group). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025. ↗
- Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022. ↗
- A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data. J Diabetes Investig. 2024. ↗
- Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA: A Review. Int J Mol Sci. 2024. ↗
- McCrimmon RJ, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity. J Endocr Soc. 2021. ↗
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. ↗
- Au Yeung SL, et al. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024. ↗
- Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis. J Eur Acad Dermatol Venereol. 2025. ↗
- Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024. ↗
- Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide. In: StatPearls [Internet]. 2024. ↗
- Aroda VR, et al. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clin Diabetes. 2023. ↗
- Weghuber D, et al. (STEP TEENS Investigators). Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022. ↗